Cost-effectiveness evaluation of routine histoplasmosis screening among people living with advanced HIV disease in Latin America and the Caribbean.
Journal
PLOS global public health
ISSN: 2767-3375
Titre abrégé: PLOS Glob Public Health
Pays: United States
ID NLM: 9918283779606676
Informations de publication
Date de publication:
2023
2023
Historique:
received:
30
01
2023
accepted:
03
07
2023
medline:
15
8
2023
pubmed:
15
8
2023
entrez:
15
8
2023
Statut:
epublish
Résumé
Histoplasma antigen can be detected in people with advanced HIV disease (AHD), allowing for early and accurate diagnosis of histoplasmosis. The aim of this analysis was to assess the cost-effectiveness of routine histoplasmosis screening using antigen detection, among people with AHD. We developed a decision analytic model to evaluate Histoplasma antigen screening among people with AHD. The model estimated the costs, effectiveness, and cost-effectiveness of routine screening for Histoplasma antigen compared to the current practice of no routine Histoplasma antigen screening. The model includes stratification by symptoms of histoplasmosis, severity of presentation, and estimates of 30-day mortality. Data sources were taken from the Pan American Health Organization (PAHO) Strategic Fund databases on public purchases of medicines, and published literature on treatment outcomes. Outcome measures are life years saved (LYS), costs (US dollars), and incremental cost-effectiveness ratios (ICERs). Routine Histoplasma antigen screening avoids an estimated 17% of deaths in persons with advanced HIV disease, and is cost-effective compared to no histoplasmosis screening, with an ICER of $26/LYS. In sensitivity analysis assuming treatment for histoplasmosis with liposomal amphotericin, Histoplasma antigen screening remains cost-effective with an ICER of $607/LYS. Histoplasma antigen screening among people with AHD is a cost-effective strategy and could potentially avert 17% of AIDS-related deaths. Prospective evaluation of histoplasmosis screening is warranted to determine effectiveness and treatment outcomes with this strategy.
Identifiants
pubmed: 37582115
doi: 10.1371/journal.pgph.0001861
pii: PGPH-D-23-00160
pmc: PMC10427011
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e0001861Informations de copyright
Copyright: This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Fungi (Basel). 2019 Aug 18;5(3):
pubmed: 31426618
Lancet Infect Dis. 2018 Oct;18(10):1150-1159
pubmed: 30146320
Lancet Infect Dis. 2020 Aug;20(8):890-892
pubmed: 32619435
J Fungi (Basel). 2022 Apr 28;8(5):
pubmed: 35628715
Microorganisms. 2021 Dec 16;9(12):
pubmed: 34946197
J Fungi (Basel). 2021 Sep 24;7(10):
pubmed: 34682221
Cochrane Database Syst Rev. 2020 Apr 28;4:CD013594
pubmed: 32343003
Rev Soc Bras Med Trop. 2018 Mar-Apr;51(2):155-161
pubmed: 29768547
PLoS Negl Trop Dis. 2014 Aug 21;8(8):e3100
pubmed: 25144374
N Engl J Med. 2022 Mar 24;386(12):1109-1120
pubmed: 35320642
J Int AIDS Soc. 2018 Mar;21(3):e25096
pubmed: 29603888
Open Forum Infect Dis. 2019 Apr 13;6(4):ofz073
pubmed: 30997365
J Fungi (Basel). 2021 Apr 01;7(4):
pubmed: 33916153
J Fungi (Basel). 2019 Dec 13;5(4):
pubmed: 31847076
Am J Trop Med Hyg. 2017 Jul;97(1):42-48
pubmed: 28719316
BMC Infect Dis. 2022 May 17;22(1):475
pubmed: 35581552
AIDS. 2016 Jan;30(2):167-70
pubmed: 26684816
Lancet Infect Dis. 2022 Dec;22(12):1748-1755
pubmed: 36049486
J Clin Microbiol. 2018 May 25;56(6):
pubmed: 29563205
J Fungi (Basel). 2019 Aug 09;5(3):
pubmed: 31404979